Entropy Neurodynamics Limited · ASX:ENP
Entropy Neurodynamics — 15th Annual Australian Microcap Investment Conference 2026
21 slides from Entropy Neurodynamics's conference presentation, May 11, 2026
Slide 1: Australian Microcap Investment Conference presentation (ASX Announcement)
ASX Announcement ASX : ENP 11 May 2026 Australian Microcap Investment Conference presentation Melbourne, Australia – Entropy Neurodynamics Limited (‘Entropy Neurodynamics’, ‘ENP’ or the ‘Company’) (ASX: ENP), a clinical-stage biotechnology company, is pleased to provide the following presentation wh
Slide 2: Risks associated with Psilocin; Forward-Looking Information
development of TRP-8803. Register for updates The Company encourages investors to register their details with Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done by: • Go to investor.automic.com.au •
Slide 3: Advancing Psychedelic Science for Disorders in Neuropsychiatry
ENTROPY NEURODYNAMICS' Advancing Psychedelic Science — for Disorders in Neuropsychiatry May 2026 This presentation has been authorised for release by the Board of Entropy Neurodynamics. Limited ASX : ENP
Slide 4: For personal use only
tives, make any warranty or representation, whether express or imped, g statements are based on a numberof assumptions wect toryterms, availabilty of equipment andsupplies, changes Plocybin is currently a Schedule il drug under the Contvoled Drugs and =o ths Presentation, i paper or electronic form,
Slide 5: Corporate Snapshot
ENTROPY NEURODYNAMICS — CORPORATE OVERVIEW Corporate Snapshot ASX code: ENP Shares on issue: 1.632Bn Market capitalisation: (at $0.035 per share) AUS5S7.1m Cash at bank: (at 31 March 2026) AUS6.5m Debt: Nil Top 20 Holders Shareholders (at 29 April 2026) Dr. William James Garner (Co-founder) 13.6% No
Slide 6: TRP-8802 (oral psilocybin) - Success in Neuropsychiatric Conditions
TRP-8802 (oral psilocybin) - SUCCESS IN 3 NEUROPSYCHIATRIC CONDITIONS - Multi-domain improvement - Binge episodes 10.8 — 0 Clinically meaningful, by Week 6 durable reduction - Pain- Sleep - Mood : Function - Depression scores halved Responders sustain benefit | , ENTROPY NEURODYNAMICS: Advancing Psy
Slide 7: FM, IBS & BED Markets Equivalent to Total Depression & Anxiety Market Size
FM, IBS & BED MARKETS EQUIVALENT TO TOTAL DEPRESSION & ANXIETY MARKET SIZE * MDD/TRD + PTSD * GAD/OCD « FM « IBS * BED
Slide 8: The Clinical Drawbacks of Oral Psilocybin Treatment
THE CLINICAL DRAWBACKS OF ORAL PSILOCYBIN TREATMENT o>) Blood level of Psilocin after taking a standard 25mg capsule of psilocybin VARIABLE ONSET (1-3 hours) Unpredictable absorption leads to inconsistent therapeutic exposure UNCONTROLLED EXPOSURE Once swallowed, the dose cannot be adjusted, slowed
Slide 9: Design the Approach to Remove the Barriers to Therapy
DESIGN THE APPROACH TO REMOVE THE BARRIERS TO THERAPY TRP-8803 : A Precision approach in Neuropsychiatry Oral Psilocybin * f i 1 1 I ' 1 1 Short treatment duration of 1-2 hours | VA ' (x) ~8-10 hours 1 ' 1 1 Quick onset of psychedelic state (~15 minutes) 1 v J (x) 12 hours ' ' t 1 I ; ; Precision ta
Slide 10: Results Phase I TRP-8803 Clinical Safety and Dose Ranging Study
RESULTS PHASE I TRP-8803 CLINICAL SAFETY AND DOSE RANGING STUDY TRP-8803 achieves consistent blood levels within a target therapeutic zone across diverse cohorts Psilocin PK Level - Normal vs Obese subjects Therapeutic Zone £ — Da £ & re 2 x7) a 40 50 60 90 120 130 150 180 240 360 480 720 MeanC2 —®=
Slide 11: Breakthrough 75% response rate in treatment-resistant IBS
ASXnnou ncement ENTROPY NEURODYNAMICS ASX : ENR, NI 4 May 2026 Breakthrough 75% response rate in treatment-resistant IBS patients in Phase 2a TRP-8802 trial Strongest clinical signal ever reported in IBS drug development Results presented at the prestigious Digestive Disease Week Congress 2026 by re
Slide 12: DDW 2026 results and comparison with IBS therapies
Presented at DDW 2026 (MGH & Columbia University) Clinically meaningful improvement in 75% of patients Subtype responses: IBS-C 100%, IBS-M 80%, IBS-D 50% Improvements in psychological flexibility & insigh Therap’ Mechanis! Population: Hieniay | Ser | (linaclotide) Trulance (plecanatide) Amitiza (lu
Slide 13: Potential Parallel Pathway for Mainstream Gastroenterology Entry
POTENTIAL PARALLEL PATHWAY FOR MAINSTREAM GASTROENTEROLOGY ENTRY Dimension Psychiatry = = Primary Endpoint Psychological scales _- Safety Oversight REMS/suicidality monitoring | Prescriber Psychiatrist | Setting Therapy room # — f 7 yj y Me y ENTROPY NFURODYNAMICS: Advancing Psychedelic: Stig for Di
Slide 14: Parallel Care Models for TRP-8803
yet = = aa Ee) Therapy Prep @) Psych Eval — + . DOSING DAY PSYCHIATRY CARE MODEL — TRD / PTSD / GAD / AN / BED — "antenatal th “PSYCHOTHERAPY + PSYCHEDELIC SESSION m4 = PARALLEL CARE MODELS FOR TRP-8803° GASTROENTEROLOGY CARE MODEL - > IBS=C/1BS-™ — INFUSION-BASED NEUROMODULATION ~=~-" “') . J ——_——
Slide 15: Global M&A Transactions in the Psychedelic Space
GLOBAL M&A TRANSACTIONS IN THE PSYCHEDELIC SPACE IMPLICATIONS FOR TRP-8803 AG + Precision-Controlled IV Psilocin ABBVIE TO ACQUIRE GILGAMESH PHARMA'S BRETISILOCIN + Phase 2a Tryptamine + Rapid Acting IV Bolus + Single 40-Patient MDD Study + Early-Stage Validation OTSUKA TO ACQUIRE TRANSCEND THERAPEU
Slide 16: Transforming Policy into Mainstream Medical Integration
* Expedited FDA Review Pathways * CMS & VA Coverage Evaluation * HHS, VA, DoD, NIH, SAMHSA * Adaptive Trial Designs *® Medicare & Medicaid Potential * Clinical Infrastructure Expansion * Accelerated Approvals * Cost-Effective Treatments * National Research Initiatives Transforming Policy into Mainst
Slide 17: Why This Matters for TRP-8803
WHY THIS MATTERS FOR TRP-8803 REGULATORY REIMBURSEMENT COMMERCIAL TAILWIND READINESS ACCELERATION GA || | + Accelerated FDA Pathways * Coverage Evaluation * Legitimate Category * Precision IV Psilocin * Cost-Effective Model + Partnering Opportunities |» Mechanism-Validated © Mainstream Adoption * Sc
Slide 18: Why the Executive Order Expands TRP-8803's Strategic Window
WHY THE EXECUTIVE ORDER EXPANDS TRP-8803’S STRATEGIC WINDOW * Oral Psilocybin Accelerated + EEG-Guided Data * Precision Delivery Demand * 2-3 Year Scaling Challenge * Predictive Algorithm * Rapid Integration Ready * Next-Gen Precision Solution * Control & Reproducibility * Scalable Platform TRP-8803
Slide 19: Global Intellectual Property Portfolio
GLOBAL INTELLECTUAL PROPERTY PORTFOLIO Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and treatment of specific disease indications have been filed for all major global pharmaceutical markets Family 1: Improved methods for the use of psychedelics
Slide 20: Upcoming Inflection Points
UPCOMING INFLECTION POINTS CLINICAL PROGRESS MANUFACTURING READINESS PLATFORM DEVELOPMENT = = coxa alles * Cohort 1 Clinical Readout Q3 2026 * Phase 2/3 Supply Agreement Q3 2026 * Integration of EEG Datasets Q4 2026 + Scale-Up Manufacturing Runs * Stability & Release Testing Q1 2027 * Full Clinical
Slide 21: Contact
ENTROPY NEURODYNAMICS' ) CONTACT Jason Carroll Henry Jordan Chief Executive Officer Six Degrees Investor Relations jcarroll@tryptherapeutics.com henry.jordan@sdir.com.au Website: Socials: www.entropyneurodynamics.com X (Twitter) @tryptherapeutic
Entropy Neurodynamics — 15th Annual Australian Microcap Investment Conference 2026 on 6ix